CEO, a former research director at LG Life Sciences, has 23 years’ experience in drug discovery and development in many therapeutic areas including antibiotics, anti-coagulants, and anticancer. He had experienced in a number of joint researches, co-developments and out-licensing deals with global pharmaceutical companies. He was also one of the key members in discovery and development of “Factive(Quinolone antibiotics)”, which was the first US FDA approved drug in Korea(launched in 2003).

Education

• B.A. in Chemistry, Seoul National University
• M.A. in Organic Chemistry, KAIST
• Ph.D. in Organic Chemistry, KAIST

Career

• Group Leader, New Drug Research Center, LG Chem Research Institute (‘83 ~ ’05)
• Director, LG Biomedical Institute, San Diego, U.S.
• Director, LG New Drug Research Center

Awards

• Dong-top Industry Award (Cephalosporin antibiotic)
• LG Grand Research Award (Cephalosporin antibiotic)

Key Research Projects

• R&D in new Cephalosphorin antibiotic and export of know-how (Glaxo, U.K.)
  • The 1st L/O new drug candidate discovery to overseas in Korea
• Antibiotics (including “FACTIVE” approved by US FDA)
• Experienced in the field of new drug R&D for more than 23 years
  • Candidate discovery (four), pre clinical/ phase 1 clinical (one each), phase 2 clinical (two), FDA approval (one), etc.
  • Anti-thrombotics, Antibiotics, Anti-coagulant, Anticancer(CDK, Ftase, RTK), HBV, HIV, HCV/HCMV, Anti-obesity, Anti-diabetics, Alzheimer, Caspase Inhibitor
  • Experienced in various joint research projects with global drug manufacturers & Licensing deal
  • Embody a fast-track discovery of a new drug candidate by utilizing a strategic guideline, so-called ‘Gate Decision System’

Education

• B.A. in Chemistry, Seoul National University
• Ph.D. University of Houston
• Post-Doc, University of California, San Diego

Career

• Research Fellow, LG Life Sciences
• Director, Center for Open Innovation, LG Life Sciences
• Director, Scripps Korea
• Vice President, Bioneer, Inc. 

Key Research

• LB20057, an oral anticoagulant out-licensed to Parke-Davis (currently Pfizer)
• LB84451, an investigational pan-caspase inhibitor for patients chronically infected with the hepatitis C virus, out-licensed to Gilead Sciences.

Education

• B.S. in Biology, Sungkyunkwan University
• M.S. in Molecular Biology, Gwangju Institute of Science and Technology
• Ph.D. in Developmental Biology, University of Virginia
• Post-Doc, Harvard University

Career

• Director of Therapeutic RNA Development, Bioneer, Inc. 

Education

• B.A. in Economics, Korea University

Career

• LG Chem (‘87 ~ ’02)
  • Purchasing, Budgeting, Strategy Planning
  • HR Team Leader, Strategy Planning Team Leader
• LG BMI (New Drug Research Branch of LGLS, San Diego, U.S.)
  • General Manager (‘96 ~ ’99)